Pfizer and Blackstone Life Sciences Announce Strategic Funding Agreement for Obesity Program
Business Wire•11/11/2026•16:30 ET
3
Key Highlights
- ➤Blackstone to fund up to $1.5 billion of Pfizer’s berobenatide development costs through 2028
- ➤Pfizer retains full operational control and decision-making for the berobenatide program
- ➤Pfizer plans 20+ obesity and comorbidity trials in 2026
- ➤Berobenatide program includes 10 ongoing and planned Phase 3 trials
- ➤Blackstone receives potential milestone payments tied to approval and commercial sales
Expert Statements
Cecile Guegan, Chief Financial Officer and Executive Vice President, Pfizer
“Our aim is to bring important new medicines to patients while taking a disciplined approach that pairs internal research investments with targeted investment from capital partners. Today’s announcement helps us advance our comprehensive obesity program and maintain the financial capacity and flexibility to invest in our broader pipeline across all therapeutic areas.”
Nicholas Galakatos, Global Head of Blackstone Life Sciences
“We are pleased to further expand our relationship with Pfizer and support the broad and rigorous development of berobenatide as the anchor of Pfizer’s cardiometabolic pipeline. This collaboration is a good example of our leadership in providing capital solutions at scale to advance important medicines and technologies to patients.”
Pfizer and Blackstone Life Sciences Announce Strategic Funding Agreement for Obesity Program
Blackstone to provide Pfizer up to $1.5 billion through 2028 to support clinical program for GLP-1 receptor agonist
Get started
Create a free account to read the full story.